Dr. Bose, of the University of Texas MD Anderson Cancer Center, discusses the novel therapies in myelofibrosis (MF) he is most excited about.
“MF is clearly a bigger unmet need,” he began. “Median survival is still in the range of six-and-a-half to seven years.”
New therapies, such as TP-3654, are currently being explored in combination studies.
“[TP-3654] is now entering combination studies with ruxolitinib and momelotinib,” Dr. Bose explained. “Momelotinib is the most recent [Janus kinase] inhibitor approved in September that improves anemia and spleen symptoms.”